Analysts Expect Radius Health Inc (RDUS) Will Post Quarterly Sales of $25.47 Million
Analysts expect Radius Health Inc (NASDAQ:RDUS) to announce sales of $25.47 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Radius Health’s earnings, with the lowest sales estimate coming in at $23.41 million and the highest estimate coming in at $27.00 million. Radius Health reported sales of $13.47 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 89.1%. The business is expected to report its next earnings report before the market opens on Thursday, November 1st.
On average, analysts expect that Radius Health will report full year sales of $96.24 million for the current financial year, with estimates ranging from $88.08 million to $105.79 million. For the next year, analysts expect that the company will report sales of $169.69 million, with estimates ranging from $150.47 million to $188.61 million. Zacks’ sales averages are an average based on a survey of analysts that follow Radius Health.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.99) EPS for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.36. The company had revenue of $22.63 million for the quarter, compared to the consensus estimate of $20.84 million. Radius Health had a negative return on equity of 110.71% and a negative net margin of 444.70%.
Shares of Radius Health stock traded up $0.68 during trading hours on Friday, reaching $19.21. The stock had a trading volume of 493,037 shares, compared to its average volume of 836,427. The company has a market cap of $809.48 million, a price-to-earnings ratio of -3.31 and a beta of 0.95. The company has a debt-to-equity ratio of 1.26, a current ratio of 5.39 and a quick ratio of 5.26. Radius Health has a 1 year low of $16.71 and a 1 year high of $41.16.
In related news, major shareholder Growth N. V. Biotech bought 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 25th. The shares were acquired at an average cost of $27.28 per share, for a total transaction of $1,364,000.00. Following the acquisition, the insider now owns 6,250,913 shares in the company, valued at approximately $170,524,906.64. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Growth N. V. Biotech bought 60,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 8th. The shares were bought at an average price of $22.73 per share, for a total transaction of $1,363,800.00. Following the completion of the acquisition, the insider now owns 6,360,913 shares in the company, valued at approximately $144,583,552.49. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 389,363 shares of company stock worth $8,675,131. Company insiders own 3.42% of the company’s stock.
Several large investors have recently made changes to their positions in RDUS. Swiss National Bank raised its holdings in shares of Radius Health by 5.6% during the 1st quarter. Swiss National Bank now owns 57,000 shares of the biopharmaceutical company’s stock valued at $2,049,000 after buying an additional 3,000 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in shares of Radius Health by 4.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 191,510 shares of the biopharmaceutical company’s stock valued at $6,883,000 after buying an additional 8,935 shares during the period. Aperio Group LLC purchased a new stake in shares of Radius Health during the 1st quarter valued at about $231,000. OppenheimerFunds Inc. purchased a new stake in shares of Radius Health during the 1st quarter valued at about $29,903,000. Finally, Farallon Capital Management LLC raised its holdings in shares of Radius Health by 3.8% during the 1st quarter. Farallon Capital Management LLC now owns 4,086,300 shares of the biopharmaceutical company’s stock valued at $146,862,000 after buying an additional 150,000 shares during the period.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Featured Article: What is the yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.